Personalis Reports Strong Q1 Clinical Growth, Secures Lung Cancer Medicare Coverage, and Raises $21M via ATM at Premium
PSNL sits 51% above its 52-week low of $3.84.
Summary
Personalis, Inc. announced Q1 2026 financial results, highlighting a 258% year-over-year increase in clinical test volume, new Medicare coverage for lung cancer, and the successful raise of $21.0 million through its At-The-Market program at a premium price.
Key Events · Earnings and Guidance · PSNL
-
Strong Clinical Volume Growth
Clinical test volume surged 258% year-over-year and 26% sequentially to 7,815 tests in Q1 2026, reflecting strong market demand for the NeXT Personal test.
-
Secures Medicare Coverage for Lung Cancer
Received Medicare coverage approval for surveillance of cancer recurrence in Stage I to III non-small cell lung cancer (NSCLC) patients, marking the second major coverage decision in six months alongside breast cancer.
-
Successful ATM Capital Raise
Ended the quarter with approximately $233.2 million in cash, cash equivalents, and short-term investments, including $21.0 million in net proceeds from the At-The-Market (ATM) sales program, executed at a weighted-average price of $10.00 per share.
-
Reaffirmed Full-Year 2026 Guidance
Reaffirmed full-year guidance, projecting total revenue of $78.0 to $80.0 million, clinical test volume of 43,000 to 45,000 tests (171% growth), and clinical revenue of $10.0 to $11.0 million (roughly five-fold growth).
Analysis · PSNL · Industrial Applications And Services
Personalis, Inc. reported first-quarter results demonstrating significant progress in its 'Win-in-MRD' strategy. The substantial increase in clinical test volume and the critical Medicare coverage approval for lung cancer surveillance are key milestones for commercialization. While overall revenue declined due to a planned shift away from non-core services and net loss increased, these are expected as the company invests heavily in its strategic growth areas. The successful ATM capital raise at a price significantly above the current market price provides a strong financial runway and indicates institutional confidence, further bolstering the company's ability to execute its growth plans.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 36.8% of the 988 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.55%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PSNL was trading at $5.78 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $627M. The 52-week trading range was $3.84 to $11.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.